Analyst Flags Safety Risks in Pyxis Oncology's Cancer Drug, Shares Drop 9%
PYXS has more than doubled off its 52-week low of $1.03 on elevated volume (2.8× avg).
Summary
William Blair analyst Andy Hsieh called MICVO's safety profile a key liability despite encouraging efficacy, noting 54% of patients had grade 3+ treatment-related adverse events and 14% discontinued. The stock fell 9.25% to $3.53 as the market weighed the safety concerns against the 36% confirmed response rate. This follows the company's earlier release of the same Phase 1 data, but the analyst's negative safety framing and the sharp price drop are new developments. The company plans an FDA meeting in Q1 2027 to finalize dosing, with a Phase 3 trial expected to start mid-2027.
At the time of this announcement, PYXS was trading at $3.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $291.9M. The 52-week trading range was $1.03 to $5.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.